obinutuzumab,zanubrutinib
beigene,roche,biogen
['obinu', 'zanubrutinib', 'follicular', 'rosewood', 'lymphoma']
just in from the rosewood phase ii trial results a promising combo therapy for r/r follicular lymphoma, zanubrutinib + obinutuzumab, offers a favorable benefit-risk profile &amp; orr, crr, median pfs, 18-mo dor, &amp; 18-mo os probability superior to obinutuzumab monotherapy #eha2022 
Real time, on-demand personalized cancer education and support through our online educational platform